CRBU (Caribou Biosciences) FFO


CRBU Caribou Biosciences Inc CRBU
66 GF Score
Price $1.67
GF Value $1.70
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Caribou Biosciences FFO?

FFO (Funds from operations) only applies to REITs.

CRBU
66GF Score
Caribou Biosciences Inc CRBU
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Caribou Biosciences (CRBU) Overvalued in 2026?

Based on GuruFocus' analysis, Caribou Biosciences stock appears to be undervalued. The current stock price of $1.67 is trading 1.8% below its estimated GF Value™ of $1.70. GuruFocus considers Caribou Biosciences to be Fairly Valued.

Key valuation signals for CRBU:

  • FFO:
  • GF Value™: $1.70 vs. price of $1.67 (1.8% below fair value)
  • GF Score™: 66/100 with 5 warning signs

No single metric tells the full story. See the CRBU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Caribou Biosciences Business Description

Address 2929 7th Street, Suite 105, Berkeley, CA, USA, 94710
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
66GF Score

Get the complete analysis for CRBU

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.67
Price
$1.70
GF Value